Know Cancer

forgot password

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

Phase 1
18 Years
Not Enrolling
Advanced Solid Tumors

Thank you

Trial Information

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

Inclusion Criteria

Inclusion Criteria

A subject is eligible for inclusion in this study only if all of the following criteria

1. Written informed consent.

2. Age 18 years or more.

3. Performance status of 0, 1, or 2 on the Eastern Co-operative Oncology Group (ECOG)

4. A predicted life expectancy of at least 3 months, in the estimation of the

5. Subjects with histologically or cytologically confirmed advanced solid tumors, who
have failed conventional therapy for their tumor type or have a tumor type for which
no standard effective therapy exists.

6. At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery.
Subjects must be free of post-treatment side effects. No concurrent chemotherapy,
biologic therapy or radiotherapy is allowed.

7. Hematological/clinical chemistry criteria of:

Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,500/mm3 [≥ 3.5 x 109/L] Neutrophils ≥ 1,500/mm3 [≥ 1.5
x 109/L] Platelets ≥ 100,000/mm3 [≥ 100.0 x 109/L] Calculated creatinine clearance
≥60 mL/min using the Cockcroft-Gault Formula.

8. Serum bilirubin < 2.0 mg/dL (34 µmol/L)

9. SGOT/AST, SGPT/ALT and alkaline phosphatase < 2 times the upper limit of normal if
liver metastases cannot be visualized by abdominal computed tomography (CT) or
magnetic resonance imaging (MRI scan). If liver metastases are present, subjects with
< 5 times the upper limit of normal are eligible to participate.

10. Once the RP2D is established, additional patients enrolled at the expanded dose
cohort must have tumor that is accessible to two serial biopsies and that is
documented (by IHC or RT-PCR) to express S14.

Exclusion Criteria

A subject is ineligible if any of the following criteria apply:

1. Cancer cachexia, defined by the combination of: unintentional weight loss ≥10%, low

caloric intake (≤ 1500 kcal/day), and systemic inflammation (C-reactive protein ≥

2. Type II diabetes mellitus

3. Women who are pregnant or lactating, or women subjects of childbearing potential who
refuse to practice adequate contraception. (oral contraceptives or IUD; double
barrier such as diaphragm plus spermicide; vasectomized partner who is sterile prior
to the female subject's entry and is the sole sexual partner of that female).
Childbearing potential is defined as women who are not surgically sterilized (i.e.
have not had a hysterectomy, bilateral oophorectomy [ovariectomy], or bilateral tubal
ligation) or post-menopausal (i.e., documented absence of menses for one year prior
to entry into the study).

4. Men unwilling to abstain from sex or use effective contraception during the study.

5. Subjects with uncontrolled emesis, regardless of etiology.

6. Active infection, or seropositivity for HIV or Hepatitis B/C.

7. Subjects with clinical evidence of any gastrointestinal (GI) conditions (i.e.,
removal of a portion of the stomach, recent GI obstruction or GI neuropathy) or
subjects taking drugs that would alter GI absorption or motility (e.g., cisapride).

8. Intercurrent severe medical problems, which would significantly limit full compliance
with the study or expose the subject to unnecessary risk.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

To define a tolerable dose of oral CLA, given on a daily schedule, that maximally inhibits S14 expression in adipocytes of patients with advanced solid tumors.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Raymond P Perez, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Kansas


United States: Food and Drug Administration

Study ID:




Start Date:

March 2010

Completion Date:

June 2013

Related Keywords:

  • Advanced Solid Tumors
  • Conjugated Linoleic Acid
  • Clarinol
  • S14 Expression
  • Neoplasms



Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer CenterLebanon, New Hampshire  03756